Compare HubSpot Inc (HUBS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Neurocrine Biosciences Inc — how do they compare? HubSpot Inc trades at $229.3 (market cap $11.56B), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HUBS | NBIX | |
|---|---|---|
Market Cap | $11.56B | $14.36B |
Volume | 1,891,287 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $494.58 | $185.50 |
52-Week Low | $170.39 | $123.10 |
Typical Hold Time | 78 Days | 23 Days |
Enterprise Value | $10.46B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $228.96, up 3.93% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth, reaching $3.13B in 2025 with net income turning positive at $45.91M. Recent analyst day highlighted AI strategy enhancements and margin expansion targets, while institutional buying and positive earnings beats support investor confidence. Technical indicators show the stock trading near pivot point resistance at $228 with RSI suggesting potential overbought conditions.
Outlook remains positive with 57% analyst buy ratings and $243.65 consensus target, though high P/E of 82.5x demands sustained growth execution. Key risks include AI competition pressure and valuation sensitivity to earnings momentum. The transition to profitability and strong cash flow generation provide fundamental support for continued upside potential.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
